Mepolizumab (a-il-5 antibody) (DrugBank: Mepolizumab)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01705795 (ClinicalTrials.gov) | February 13, 2013 | 5/10/2012 | Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. | Pemphigoid, Bullous | Drug: Mepolizumab (a-IL-5 antibody);Drug: Placebo | University Hospital Inselspital, Berne | NULL | Completed | 18 Years | N/A | All | 32 | Phase 2 | Switzerland |